Press Release
March 30, 2020

ElevateBio Closes $170 Million Series B Financing

The Life Sciences team advised ElevateBio, LLC, on its $170 Million Series B financing that will support and accelerate the company’s next phase of growth. New investors, The Invus Group, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures, join existing investors, F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, and Samsara BioCapital, all of whom also participated in this financing.

ElevateBio is a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies.

The Series B proceeds will enable ElevateBio BaseCamp to be fully operational with cGMP manufacturing;  the advancement of clinical development with at least six cell and gene therapies from across its portfolio companies to enter clinical studies this year and into 2021; and key milestones and continued development of ElevateBio’s enabling technology platforms.

The Goodwin team was led by Danielle Lauzon and included Gaby Morales-Rivera, Kimberly Maruncic and Katie Hand (Corporate) and Dan Karelitz (Tax).

For more details, read the press release and articles in TechCrunch, Boston Business Journal and Endpoints.